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Abstract
Background: Depression is known to be a risk factor for cardiovascular diseases but the underlying mechanisms
remain unclear. Since recent preclinical evidence suggests that endogenous agonists of cannabinoid receptors
(endocannabinoids) are involved in both cardiovascular function and depression, we asked whether
endocannabinoids correlated with either in humans.
Results: Resting blood pressure and serum content of endocannabinoids in ambulatory, medication-free, female
volunteers with depression (n = 28) and their age- and ethnicity-matched controls (n = 27) were measured. In
females with depression, both diastolic and mean arterial blood pressures were positively correlated with serum
contents of the endocannabinoids, N-arachidonylethanolamine (anandamide) and 2-arachidonoylglycerol. There
was no correlation between blood pressure and endocannabinoids in control subjects. Furthermore, depressed
women had significantly higher systolic blood pressure than control subjects. A larger body mass index was also
found in depressed women, however, it was not significantly correlated with serum endocannabinoid contents.
Conclusions: This preliminary study raises the possibility that endocannabinoids play a role in blood pressure
regulation in depressives with higher blood pressure, and suggests an interrelationship among endocannabinoids,
depression and cardiovascular risk factors in women.
Keywords: Depression, Systolic blood pressure, Diastolic blood pressure, Cardiovascular risk, Anandamide,
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Background
Recently, the lipid signaling molecules endocannabinoids
(eCBs) have been linked to depression and anxiety dis-
orders [1-5]. The eCBs are endogenous agonists of can-
nabinoid CB1 and/or CB2 receptors and the prototypical
examples are N-arachidonylethanolamine (anandamide;
AEA) and 2-arachidonoylglycerol (2-AG). These hydro-
phobic molecules are produced ‘on demand’ in the cen-
tral and peripheral system by stimuli, such as
depolarization, increases in intracellular Ca
2+ and activa-
tion of G protein-coupled receptors linked to phospholi-
pase cascades [6,7]. Interestingly, cannabinoid CB1
receptor knock-out mice display biochemical and
behavioral changes that are often seen in depression,
including increased activity of the hypothalamus-pitui-
tary-adrenal axis, anxiety, anhedonia, reduced feeding
and weight loss [2,8,9]. Alterations in eCB contents and/
or CB1 receptor signaling have also been associated with
stress and depression in laboratory animals, depending
on the context, stressor and brain region [3-5]. It
remains to be established whether or not pathological
changes in eCB contents worsen or alleviate symptoms
of depression. In an attempt to investigate this, we have
previously examined the serum content of eCB in
women diagnosed with depression [10,11]. We observed
that serum content of AEA and 2-AG was increased in
minor depression but decreased in major depression,
suggesting that the endocannabinoid system may be dis-
turbed in depressive disorders. There is also indication
that circulatory eCBs levels are correlated with exposure
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supported by the recent findings that variations of the
gene encoding CB1 receptors is associated with depres-
sive symptoms [12] and a reduction in antidepressant
treatment response in major depression, especially in
women with high anxiety level [13].
Depression is not only a persistent mood disorder, but
also a risk factor for cardiovascular diseases. It is preva-
lent in heart failure patients and predicts poor prognosis
for those with ischemic heart disease or following myo-
cardial infarction [14,15]. The underlying mechanisms of
this association are unclear but the higher occurrence of
hypertension and changes in cardiac and arterial func-
tions in depressed patients could play a role. For
instance, depression has been associated with impaired
autonomic control, enhanced platelet reactivity, upregu-
lation of proinflammatory mediators and development
of atherosclerotic plaques [14-17]. AEA and 2-AG are
known to modulate cardiovascular functions [18]. In
rodents, AEA and/or 2-AG can cause arterial dilation
[19,20], reduced cardiac contractility [21] and hypoten-
sion [22,23]. Furthermore, AEA and other CB1 receptor
agonists modulate autonomic transmission [24,25], pla-
telet reactivity [26,27] and inflammatory processes [28],
all of which have been implicated in the cardiovascular
risks associated with depression in humans. These data
lead us to hypothesize that eCBs are involved in the
interaction between depression and cardiovascular func-
tion. Using the same cohort of volunteers as in our
recent study [10], we have examined the relationship
between serum eCB content and resting blood pressure
in depressed women.
Results
Correlations between serum eCBs and blood pressure in
depressed individuals
The average systolic blood pressure was significantly
higher in depressed individuals than their matched con-
trols (Table 1). There were no significant overall differ-
ences in their averaged diastolic pressure, mean arterial
pressure or heart rate (Table 1); however further analy-
sis found that these parameters were significantly
increased in minor as compared to major depression
(Table 1).
Pooling data from all depressed subjects masked the
bidirectional changes in serum eCB contents in minor
versus major depression [10], such that the averaged
serum AEA and 2-AG contents were similar in
depressed women (AEA: 0.8 ± 0.1 pmol/ml; 2-AG: 18.5
± 2.7 pmol/ml) and in control subjects (AEA: 0.7 ± 0.1
pmol/ml; 2-AG: 19.0 ± 2.4 pmol/ml). However, we
found that both serum AEA and 2-AG were positively
correlated with diastolic and mean arterial pressure in
the combined group of women diagnosed with major
and minor depression (Table 2). Based on Pearson’s
Correlation tests (r), it was estimated that about 20% to
38% of variance in eCB content could be explained by
variation in diastolic pressure or mean arterial pressure
in women with depression, and vice versa. In addition,
AEA tended to correlate positively with systolic pressure
or heart rate (Table 2); it might account for > 11% of
the variance in systolic pressure and heart rate. In con-
trast, no correlations between serum eCBs and blood
pressure or heart rate were found in the control subjects
(Table 2). The distinct distributions of serum eCBs in
relation to blood pressure readings in control and
depressed subjects are shown in Figure 1 (for AEA) and
Figure 2 (for 2-AG). Importantly, significant correlations
between eCBs and diastolic pressure, and between eCBs
and mean blood pressure, were also obtained after con-
trolling for a third variable; use of tobacco (% daily smo-
kers, Depressives, 25%; Control: 0%), use of oral
contraceptives (% user, Depressives, 18%; Control: 30%),
alcohol consumption (number of alcoholic drinks per
week, Depressives, 2.6 ± 0.9; Control, 1.3 ± 0.7), BMI
(see below), waist-to-hip ratio (see below) or serum total
cholesterol levels (data not shown).
BMI values were significantly elevated in depressed
women (Table 1). It was noted that 2 of the depressed
patients would be considered for hypertensive treatment
(with systolic/diastolic: 152/91 and 140/84 mmHg) and
had a BMI of 59 and 29 kg/m
2 respectively. In both the
control and depressed subjects, BMI was positively cor-
related with systolic pressure (Depressive: r = .41, P =
0.03; Control: r = .38, P = 0.05) but not diastolic
Table 1 Cardiovascular parameters and body mass index
MAP (mmHg) SBP (mmHg) DBP (mmHg) HR (beats/min) BMI
(kg/m
2)
Control 81.4 ± 1.6 108.6 ± 1.5 67.9 ± 1.5 70.0 ± 1.8 25.4 ± 1.0
Depressed patients 85.6 ± 1.7 115.1 ± 2.1* 69.8 ± 1.3 69.0 ± 2.0 31.5 ± 1.8**
Minor depression 89.7 ± 3.3*† 118.2 ± 4.0* 73.7 ± 2.3*†† 71.9 ± 3.2†† 31.9 ± 3.2**
Major depression 82.6 ± 1.4 112.9 ± 2.1 66.9 ± 1.2 66.8 ± 2.4 31.2 ± 2.2**
* P < 0.05, ** P < 0.01 vs control; † P < 0.05, †† P < 0.01 vs patients with major depression; MAP, mean arterial blood pressure; SBP, systolic blood pressure; DBP,
diastolic blood pressure; HR: heart rate; BMI, body mass index
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P = 0.97). In depressed subjects, BMI was also positively
correlated with mean arterial pressure (Depressive: r =
.40, P = 0.03; Control: r = .15, P =0 . 4 6 ) .H o w e v e r ,B M I
was not correlated with serum eCBs in either group
(Depressives, AEA: r = .28, P = 0.15; 2-AG: r = .03, P =
0.88; Control, AEA: r = -.02, P = 0.93; 2-AG: r = .05, P
= 0.82).
As in the case for BMI, waist-to-hip ratio, which is an
indicator of abdominal obesity, of depressed subjects
(0.82 ± 0.01) was also significantly larger than that of
control subjects (0.79 ± 0.01; P = 0.01). In control sub-
jects, 2-AG was significantly and positively correlated
with waist-to-hip ratio but no other correlations were
significant (Depressives, AEA: r = -.03, P = 0.90; 2-AG: r
= .23, P = 0.24; Control, AEA: r = .28, P = 0.17; 2-AG: r
= .41, P = 0.03).
Table 2 Correlation between serum endocannabinoids
and blood pressure in depression
AEA 2-AG
r* P† rP
Control n = 27 MAP -.07 0.72 -.06 0.78
SBP -.17 0.40 .04 0.83
DBP -.05 0.81 -.04 0.84
HR -.02 0.92 -.13 0.54
Depressed patients
n=2 8
MAP .50 < 0.01‡ .46 0.01‡
SBP .35 0.07 .22 0.26
DBP .46 0.01‡ .62 < 0.01‡
HR .34 0.08 .14 0.48
* correlation coefficient as determined by Pearson correlation tests; †
probability value; ‡ statistical significance; MAP, mean arterial blood pressure;
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR: heart rate
Figure 1 Scatter plots of serum content of N-arachidonylethanolamide (AEA) and mean or diastolic blood pressure in control (a, b) or
depressed subjects (c, d). n = 27-28. Serum AEA is positively correlated with mean (r = .50) and diastolic blood pressure (r = .46) in depressed
subjects (c.f. Table 2).
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between controls (183.1 ± 6.9 mg/dL) and depressed
subjects (180.7 ± 5.8 mg/dL). There was a tendency for
2-AG, but not AEA, to be positively correlated with
serum cholesterol in both groups (Depressives, AEA: r =
.08, P = 0.68; 2-AG: r = .33, P = 0.09; Control, AEA: r =
.03, P = 0.90; 2-AG: r = .33, P = 0.09). No correlation
between cholesterol and blood pressure was detected
(data not shown).
Correlations between serum eCBs and blood pressure in
major versus minor depression
We further examined if correlations between serum
eCBs and blood pressure reported herein depend on the
severity of depression. The mean arterial (P = 0.04) and
diastolic blood pressure (P = 0.01) in minor depression
was significantly greater than that in major depression
(Table 1).
In subjects with minor depression, 2-AG, but not
AEA, was strongly and positively correlated with diasto-
lic blood pressure (Table 3). Based on Pearson’s Correla-
tion tests, it was estimated that almost 51% of variance
in 2-AG content could be explained by variation in dia-
stolic pressure and vice versa. In addition, AEA was
positively correlated with heart rate in minor depres-
sives, accounting for about 32% of variance (Table 3). In
subjects with major depression, AEA, but not 2-AG, was
positively correlated with diastolic pressure (Table 3). It
was estimated that about 23% to 29% of variance of
AEA content could be explained by variation in diastolic
pressure and vice versa. AEA also tended to correlate
positively with mean arterial blood pressure (Table 3).
Figure 2 Scatter plots of serum content of 2-arachidonoylglycerol (2-AG) and mean or diastolic blood pressure in control (a, b) or
depressed subjects (c, d). n = 27-28. Serum 2-AG is positively correlated with mean (r = .46) and diastolic pressure (r = .62) in depressed
subjects (c.f. Table 2).
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stolic pressure remained significant after controlling for
a third variable, including: use of tobacco, use of oral
contraceptives, alcohol consumption, BMI, waist-to-hip
ratio or serum total cholesterol levels (data not shown).
BMI values were significantly increased in both minor
and major depression (Table 1). Interestingly, BMI was
positively correlated with systolic and mean arterial
blood pressure in individuals with minor (MAP: r = .63,
P = 0.02; SBP: r = .59, P = 0.03), but not major (MAP: r
= .00, P = 0.99; SBP: r = .09, P = 0.73), depression. BMI
was not significantly correlated with diastolic pressure
(Minor depression, r = .44, P = 0.15; Major depression,
r = .02, P = 0.95). In addition, no correlation between
eCBs and BMI was detected in either depression group
(Minor depression, AEA: r = .39, P = 0.21; 2-AG: r =
-.04, P = 0.89; Major depression, AEA: r = .13, P = 0.64;
2-AG: r = .19, P =0 . 4 8 ) .I tw a sn o t e dt h a tt h e r ew a sa
tendency for 2-AG, but not AEA, to be positively corre-
lated with serum cholesterol in minor depression
(Minor depression, AEA: r = -.05, P = 0.89; 2-AG: r =
.57, P = 0.06; Major depression, AEA: r = .10, P =0 . 7 0 ;
2-AG: r = -.05, P = 0.86).
Discussion
The major finding in this study was that serum content
of both AEA and 2-AG were positively correlated with
both diastolic and mean arterial pressure in ambulatory,
medication-free, women with depression. We also found
that diastolic pressure was positively correlated with 2-
AG in minor depression but with AEA in major depres-
sion, hinting at a differential role of the eCBs in depres-
sion. Our data also confirm previous suggestions that
depression is accompanied by elevated blood pressure,
which is a major risk factor for cardiovascular diseases.
T oo u rk n o w l e d g e ,t h i si st h ef i r s tr e p o r to fa
correlation between eCBs and blood pressure in clinical
depression. This correlation, however, does not necessa-
rily imply a casual relationship. It is also important to
note that it is too early to generalize our data to a larger
population. Notably, the current data were obtained in
relatively young, female volunteers. Therefore it remains
to be determined if similar results also occur in older
subjects and in men.
By still unknown mechanisms, depression seems to
have a negative impact on basic cardiovascular func-
tions. For instance, reductions in heart rate variability
[15] and baroreflex sensitivity [17] as well as increases
in blood pressure or hypertension [29] have been
reported in depressed patients. These changes might
explain why depression is a risk factor for cardiovascular
diseases, and increases mortality and morbidity in
patients with myocardial infarction or heart failure
[14,15]. In this study, we found that depressed women
have significantly higher systolic pressure (by an average
of 6.5 mmHg) and also tend to have a higher mean
arterial pressure (by an average of 4.2 mmHg). Interest-
ingly, increases in systolic and mean arterial blood pres-
sure are more evident in individuals with minor, as
compared to major, depression. For the majority of
depressed subjects, their systolic and diastolic pressures
remain within the normotensive range [30]. Neverthe-
less, it is noteworthy that several epidemiological studies
have suggested a continual and gradual increase in car-
diovascular risks with increased systolic and diastolic
blood pressure, even when pressures remain within nor-
mal range [31,32].
There is strong evidence from laboratory animals that
eCBs are involved in the regulation of blood flow and
blood pressure, especially in pathophysiological condi-
tions such as hypertension [18]. Exogenous addition of
AEA or 2-AG can reduce cardiac contraction, vascular
tone and arterial blood pressure [19-23]. Importantly,
Kunos and colleagues [22,33,34] have demonstrated that
the hypotensive effects of AEA are more pronounced in
hypertensive, anaesthetized animals. Indeed, in Sponta-
n e o u s l yH y p e r t e n s i v eR a t s ,ac o m m o n l yu s e dm o d e lf o r
genetic hypertension, inhibition of enzymatic degrada-
tion of endogenous AEA is sufficient to reduce blood
pressure [33]. Notably, modulation of eCB signaling, by
using AEA enzyme inhibitors or CB1 receptor antago-
nist, regulates blood pressure in hypertensive, but not
normotensive rats. These results suggest that an eCBs
tone limits the extent of hypertension under pathophy-
siological conditions. This might explain our observed
correlations of eCBs and blood pressure in the
depressed (hypertensive) but not in healthy subjects. On
the other hand, increases in blood pressure have
recently been shown to elevate AEA content in the reg-
ulatory center for baroreceptor reflex [35]. It has been
Table 3 Correlation between serum endocannabinoids
and blood pressure in minor versus major depression
AEA 2-AG
r* P† rP
Minor depression n = 12 MAP .44 0.15 .44 0.15
SBP .36 0.25 .22 0.49
DBP .30 0.34 .71 < 0.01‡
HR .57 0.05‡ .11 0.74
Major depression n = 16 MAP .48 0.06 -.20 0.47
SBP .21 0.43 -.23 0.40
DBP .54 0.03‡ -.30 0.26
HR -.06 0.84 -.22 0.41
In the same cohort of females, serum AEA is significantly increased in minor
depression, whereas 2-AG is decreased in major depression
11. * correlation
coefficient as determined by Pearson correlation tests; † probability value; ‡
statistical significance; MAP, mean arterial blood pressure; SBP, systolic blood
pressure; DBP, diastolic blood pressure; HR: heart rate
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might be compromised in depression [17], by increasing
neuronal activity at the nucleus tractus solitarius [35,36].
Our data that serum contents of AEA and 2-AG are
strongly and positively correlated with diastolic and
mean arterial blood pressure in depressed but not
healthy women, suggest that serum eCBs could function
to compensate for an elevated blood pressure in depres-
sion. If this is true, the data also suggest that this feed-
back mechanism fails to normalize the systolic pressure,
which remains elevated in depressives. This hypothesis
is consistent with the animal data available; however,
the possibility that eCBs somehow contribute to the
increase in blood pressure cannot be ruled out. It is
interesting that serum eCB content and blood pressure
are not correlated in control subjects. Furthermore,
despite opposing changes of averaged, serum eCB con-
tent in minor and major depression [10], either AEA or
2-AG remains positively correlated with diastolic blood
pressure in both depression groups. Taken together, the
present findings suggest that a positive correlation
between serum eCBs and blood pressure could be a
common feature of depression at different levels of
severity. It is conceivable that biochemical changes in
depression, or its associated increase in blood pressure,
play a facilitatory role in the positive correlation
between eCBs and blood pressure.
Emerging evidence suggests changes in eCB signaling
are involved in depression and anxiety disorders. In the
same cohort of female subjects as in the current study, we
observed that serum 2-AG content is negatively correlated
with the duration of current depressive episode and AEA
content is negatively correlated with Hamilton ratings for
cognitive and somatic anxiety in depressed subjects [10].
However, there is no correlation between these parameters
and blood pressure (data not shown). Together, our results
point to the complex interrelationships among serum con-
tent of eCBs, depression and blood pressure. In this study,
there is also evidence that AEA and 2-AG could play a dif-
ferential role in minor vs major depression since diastolic
pressure was positively correlated with 2-AG in minor
depression and with AEA in major depression. The synth-
esis and degradation of the two eCBs involve distinct
enzymes [6,7] and eCB levels are often differentially regu-
lated in stress and anxiety [3,10,11]. Alterations of eCBs
signaling in depression and hypertension of different
severity remain unclear but our data might indicate that 2-
AG is the predominant eCB involved in blood pressure
control in minor depression, whereas AEA plays a more
important role in major depression. Such differential roles
also highlight the need for measurements of both eCBs in
future studies on subtypes of depression.
Depression is sometimes associated with an increased
prevalence of obesity and smoking, which could act as
confounding factors in the association between blood
pressure and eCBs. In this study, depressed subjects are
more likely to be obese (with BMI ≥ 30 kg/m
2)c o m -
pared to their matched controls. Whilst this might con-
tribute to the increased blood pressure in depressives, a
direct link between BMI and serum eCBs is not evident.
In addition, tobacco smoking, the waist-to-hip ratio,
serum total cholesterol also fail to explain the correla-
tions between eCBs and blood pressure in depression. It
is noteworthy that the absence of correlation between
BMI and eCBs in the current study (in women; average
age of 29 years) contrasts with the observation that BMI
is positively correlated with plasma 2-AG, but not AEA,
in men with an average age of 42 years [37]. The discre-
pancy could also be due to the limited number of sub-
jects with advanced obesity in our sample [38].
Interestingly, however, there is indication that 2-AG, but
not AEA, is positively correlated with serum total cho-
lesterol levels in our female subjects. Since subfractions
of cholesterol content were not determined in this
study, it is unknown if high-density lipoproteins (HDL)-
cholesterol or low-density lipoproteins (LDL)-choles-
terol, or both, are involved. This is of particular interest
in light of the finding that the CB1 receptor antagonist,
rimonabant, improves serum HDL-cholesterol of over-
weight or obese subjects in a randomized, double-
blinded clinical trial [39]. Further analysis also revealed
that correlations between 2-AG and total serum choles-
terol, and between BMI and blood pressure, occurred
predominantly in individuals with minor depression. At
present, the significance of these subtle differences of
cardiovascular and metabolic variables between minor
and major depression is unclear.
To conclude, our study shows that serum contents of
eCBs are positively correlated with blood pressure in
depressed women but not in their matched control sub-
jects. We speculate that eCBs play a role in regulation
of blood pressure in depression, perhaps acting to buffer
an increase in blood pressure. In this study, depressed
women also have a higher systolic blood pressure, body
mass index, waist-to-hip ratio and higher prevalence of
tobacco smoking, all of which are associated with
increased risk of cardiovascular diseases. Since eCBs are
likely involved in both cardiovascular and neuronal
functions, the interrelationships among these agents,
cardiovascular parameters and depression warrant
further attention.
Given the negative impact of depression on patients
w h oh a v ei s c h e m i ch e a r td i s e a s eo rh a v er e c e n t l yh a d
myocardial infarction, it has been suggested that effec-
tive treatment of depression can not only improve the
quality of life but also the clinical outcome of patients
with heart diseases. A few, although not all, clinical
trials have indeed shown that treating depression with
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cantly improve the prognosis of patients recovering
from myocardial infarction [40-42]. In this regard, it is
interesting to note that inhibitors of fatty acid amide
hydrolase have been proposed to reduce the symptoms
of anxiety and depression [43,44]. Perhaps increasing
eCBs signaling by these inhibitors could also help nor-
malize blood pressure homeostasis in depression. How-
ever, this approach could also be detrimental to
depressive individuals with obesity-related co-morbid-
ities since a recent clinical study has reported that
plasma eCBs is inversely related to coronary blood flow
in advanced obesity [38]. More clinical studies examin-
ing the role of eCBs in depression and cardiovascular
functions are required.
Methods
Subjects
A total of 55 ambulatory, adult women from Saint
Louis, MO, USA participated in the study; the same
cohort of volunteers was used in our recent study [10].
The protocol was approved by the Institutional Review
Board of Washington University USA and all subjects
provided written informed consent. Depressed subjects
(n = 28, age 29.0 ± 1.7) met the diagnostic criteria
defined by the forth edition of the Diagnostic and Statis-
tical Manual (DSM-IV) [45] for clinical depression. They
included subjects with Major Depressive Episode (n =
16) and Minor Depressive Episode (n = 12). Their
matched control subjects (based on age and ethnicity; n
= 27, age 28.8 ± 1.6) had no lifetime history of psychia-
tric illness. Each group had 12 Caucasian, 13/14 African
American, 1 Hispanic and 1 Asian subjects. All subjects
were in good health, defined as having (a) no history of
chronic medical illness, (b) no indications of acute infec-
tious disease at study entry, as evidenced by self-report
of symptoms and a normal complete blood count, and
(c) no prescribed medication regimen, other than oral
contraceptives, in the past 6 months including anti-
depressants. Candidates were excluded if they were
o l d e rt h a n5 5 ;h a db e e np r e g n a n ti nt h ep a s ty e a r ;w e r e
menopausal, postmenopausal, had irregular menses;
were undernourished as evidenced by serum albumin ≤
3.3 g/dL; or with reported abuse of illicit substances
including cannabis, cocaine and heroin. More detailed
information on the recruitment of volunteers, subse-
quent assessment of clinical depression and demo-
graphic characteristics of the sample population has
previously been reported [10].
Blood pressure measurement
Subjects were seated in a comfortable chair with fore-
arm on the armrest. Using appropriate cuff size, 3 blood
pressure readings, spaced 2 min apart, were collected by
an automated oscillometric device (Dinamap Pro 100;
Critikon Corporation). The averaged systolic, diastolic
and mean arterial blood pressure were obtained. This
was followed by blood draw, via antecubital venipunc-
ture, in the morning hours (0900 h - 1200 h). Blood
samples were centrifuged for 15 min at 1000 g and the
serum aspirated and frozen at -70 to -80°C until use. All
serum samples were frozen by 120 min following veni-
puncture. Total serum cholesterol was also assessed
using enzymatic methods on a Hitachi 747 instrument
(Kyowa Medex) in the Washington University Center
for Clinical Studies. Upon completion of the study, par-
ticipants were compensated US$150. These procedures
were approved by the Institutional Review Board of
Washington University, USA.
Detection of serum endocannabinoids
Serum eCBs were extracted by using Bond Elut C18 solid-
phase extraction columns (1 ml; Varian Inc, Lake Forest,
CA). Serum samples (0.5 ml each) were thawed and made
up to 15% ethanol, to which the internal standards [
2H8]-
AEA (16.9 pmol) and [
2H8]-2-AG (46.5 pmol) (Cayman
Chemicals, Ann Arbor, MI) were added. Samples were
vortexed and centrifuged at 1000 × g for 4 min. The
supernatant was loaded on C18 columns, which have been
conditioned with 1 ml redistilled ethanol and 3 ml of dou-
ble distilled water (ddH2O). The remaining pellet was
washed with 100 μl of 15% ethanol and centrifuged again
for 3 min. The resulting supernatant was also loaded onto
the C18 column. Columns were washed with 5 ml ddH2O
and eluted with 1 ml of ethyl acetate. The ethyl acetate
layer in the resulting elute was removed and dried under
N2. Lipids in the residual ddH2O phase were extracted by
mixing with an additional 1 ml of ethyl acetate, which was
added to the original ethyl acetate solution. Once dried,
samples were resuspended in 20 μl of methanol and stored
at -80°C. AEA and 2-AG were quantified using isotope-
dilution, atmospheric pressure, chemical ionization liquid
chromatography/mass spectrometry (LC-APCI-MS) as
described previously [46].
Data and statistical analysis
We have recently detected a bidirectional change of
serum contents of AEA and 2-AG in minor versus
major depression in the same cohort of female subjects
[10]. To reveal potential, underlying relationship
between serum eCB content and resting blood pressure,
we therefore first examined data obtained from all
depressed subjects (with either major or minor depres-
sion). Further analysis was then performed to explore
the impact of the severity of depression on correlations
between serum eCBs and blood pressure.
Data are given as mean ± SEM. Blood pressure, heart
rate and BMI in individuals with depression and their
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tests or one-way analysis of variance (Prism 4.02; Graph-
Pad Software Inc). Correlations between eCB content and
blood pressure were analyzed by bivariate, Pearson’s corre-
lation tests (SPSS 14.0; SPSS Inc.). Influences of potential
confounders on these correlations were tested by control-
ling for a third variable, for example tobacco use, body
mass index (BMI) and serum cholesterol level, using par-
tial correlation tests (SPSS 14.0; SPSS Inc). P ≤ 0.05 was
considered statistically significant.
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